1306829-97-9

Basic information

• Product Name: 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenyl-
• CAS NO: 1306829-97-9
• Molecular Weight: 242.304
• Mol File: 1306829-97-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenyl-(1306829-97-9)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenyl-(1306829-97-9)

Safety Data

• Hazardous Substances Data: 1306829-97-9(Hazardous Substances Data)

Usage

Chemical Class

1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenylbelongs to the class of pyrazolopyrimidine derivatives.

Structural Features

The compound features a central ring structure with a methylthio group and a phenyl group attached to it.

Potential Applications

It has potential applications in pharmaceuticals and agrochemicals due to its structural features.

Biological Activities

The compound may exhibit biological activities such as anticancer, antiviral, or antifungal properties.

Use as Building Block

It could be used as a building block for developing new drugs or agrochemicals.

Further Research

More research is needed to fully understand the properties and potential uses of 1H-Pyrazolo[3,4-d]pyrimidine, 6-(methylthio)-3-phenyl-.

Upstream product

• 100047-42-5 6-(methylsulfanyl)-1H,2H,3H-pyrazolo[3,4-d]pyrimidin-3-one 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 1306829-95-7 3-bromo-6-(methylsulfanyl)-1H-pyrazolo[3,4-d]pyrimidine 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1350550-37-6 1-((4-aminocyclohexyl)methyl)-N-methyl-3-p-tolyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine trifluoroacetate 
• 1350550-44-5 tert-butyl 4-((6-(methylamino)-3-p-tolyl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)cyclohexylcarbamate 
• 1350550-42-3 tert-butyl 4-((3-bromo-6-(methylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)cyclohexylcarbamate 

Relevant articles and documents

Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia

Ectopic Mer expression promotes pro-survival signaling and contributes to leukemogenesis and chemoresistance in childhood acute lymphoblastic leukemia (ALL). Consequently, Mer kinase inhibitors may promote leukemic cell death and further act as chemosensitizers increasing efficacy and reducing toxicities of current ALL regimens. We have applied a structure-based design approach to discover novel small molecule Mer kinase inhibitors. Several pyrazolopyrimidine derivatives effectively inhibit Mer kinase activity at subnanomolar concentrations. Furthermore, the lead compound shows a promising selectivity profile against a panel of 72 kinases and has excellent pharmacokinetic properties. We also describe the crystal structure of the complex between the lead compound and Mer, opening new opportunities for further optimization and new template design.

PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER

Compound of Formula (I): are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.